Intellia Therapeutics (NASDAQ:NTLA) Given Neutral Rating at William Blair

William Blair reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research note published on Monday,RTT News reports. The firm currently has a $14.00 price target on the stock.

NTLA has been the subject of several other research reports. Barclays cut their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Chardan Capital increased their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday. Robert W. Baird decreased their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Citigroup decreased their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Stock Up 5.7 %

Shares of NASDAQ:NTLA opened at $13.86 on Monday. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -2.55 and a beta of 1.81. Intellia Therapeutics has a fifty-two week low of $12.82 and a fifty-two week high of $34.87. The firm’s 50-day simple moving average is $18.26 and its 200-day simple moving average is $21.85.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.38) EPS. On average, research analysts forecast that Intellia Therapeutics will post -5.13 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently made changes to their positions in NTLA. Blue Trust Inc. boosted its position in shares of Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after buying an additional 1,398 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank acquired a new stake in Intellia Therapeutics in the third quarter valued at approximately $41,000. Values First Advisors Inc. purchased a new stake in shares of Intellia Therapeutics during the third quarter valued at approximately $54,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.